Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haoda Fu

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 7, 2015
Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 6, 2015
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Journal of Biopharmaceutical Statistics|May 10, 2023
scRAA: the development of a robust and automatic annotation procedure for single-cell RNA sequencing dataDongyan Yan, Zhe Sun, Jiyuan Fang, et al.
Journal of Managed Care & Specialty Pharmacy|April 29, 2016
Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes DrugsVishal Saundankar, Xiaomei Peng, Haoda Fu, et al.
JAMA Oncology|October 5, 2017
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioKyongsun Pak, Hajime Uno, Dae Hyun Kim, et al.
Annals of Internal Medicine|June 9, 2015
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesHajime Uno, Janet Wittes, Haoda Fu, et al.
Pharmaceutical Statistics|September 17, 2013
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysisDavid Ohlssen, Karen L Price, H Amy Xia, et al.
Cell Metabolism|September 10, 2013
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetesGregory Gaich, Jenny Y Chien, Haoda Fu, et al.
Diabetes Care|December 8, 2016
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249Christof M Kazda, Ying Ding, Ronan P Kelly, et al.
Diabetes Care|April 20, 2017
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249Christof M Kazda, Ying Ding, Ronan P Kelly, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 7, 2015
Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 6, 2015
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Journal of Biopharmaceutical Statistics|May 10, 2023
scRAA: the development of a robust and automatic annotation procedure for single-cell RNA sequencing dataDongyan Yan, Zhe Sun, Jiyuan Fang, et al.
Journal of Managed Care & Specialty Pharmacy|April 29, 2016
Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes DrugsVishal Saundankar, Xiaomei Peng, Haoda Fu, et al.
JAMA Oncology|October 5, 2017
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard RatioKyongsun Pak, Hajime Uno, Dae Hyun Kim, et al.
Annals of Internal Medicine|June 9, 2015
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority StudiesHajime Uno, Janet Wittes, Haoda Fu, et al.
Pharmaceutical Statistics|September 17, 2013
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysisDavid Ohlssen, Karen L Price, H Amy Xia, et al.
Cell Metabolism|September 10, 2013
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetesGregory Gaich, Jenny Y Chien, Haoda Fu, et al.
Diabetes Care|December 8, 2016
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249Christof M Kazda, Ying Ding, Ronan P Kelly, et al.
Diabetes Care|April 20, 2017
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249Christof M Kazda, Ying Ding, Ronan P Kelly, et al.
Pageof 8